Home » Stocks » ANEB

Anebulo Pharmaceuticals, Inc. (ANEB)

Stock Price: $7.03 USD 0.02 (0.29%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 163.56M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 23.27M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $7.03
Previous Close $7.01
Change ($) 0.02
Change (%) 0.29%
Day's Open 6.90
Day's Range 6.87 - 7.03
Day's Volume 3,324
52-Week Range 6.31 - 9.33

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) released its third-quarter fiscal 2021 financial results on Tuesday with a net loss of $555,832 or $0.04 per share.  The ...

1 month ago - Benzinga

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from can...

1 month ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from can...

2 months ago - Business Wire

A fresh slate of biotech IPOs has filed to go public as the calendar turns toward the second quarter.

3 months ago - Endpoints News

Anebulo Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About ANEB

Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Our lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. There is no approved medical treatment currently available to specifically alleviate the symptoms of cannabinoid ov... [Read more...]

Industry
Biotechnology
IPO Date
May 7, 2021
CEO
Daniel Schneeberger, M.D.
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
ANEB
Full Company Profile